BR112016028520A2 - métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina - Google Patents
métodos e composições para o tratamento de transtornos com polipeptídeos de folistatinaInfo
- Publication number
- BR112016028520A2 BR112016028520A2 BR112016028520A BR112016028520A BR112016028520A2 BR 112016028520 A2 BR112016028520 A2 BR 112016028520A2 BR 112016028520 A BR112016028520 A BR 112016028520A BR 112016028520 A BR112016028520 A BR 112016028520A BR 112016028520 A2 BR112016028520 A2 BR 112016028520A2
- Authority
- BR
- Brazil
- Prior art keywords
- folistatin
- polypeptides
- compositions
- methods
- treating disorders
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 210000001519 tissue Anatomy 0.000 abstract 2
- 238000006471 dimerization reaction Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462007908P | 2014-06-04 | 2014-06-04 | |
| PCT/US2015/034245 WO2015187977A1 (en) | 2014-06-04 | 2015-06-04 | Methods and compositions for treatment of disorders with follistatin polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016028520A2 true BR112016028520A2 (pt) | 2017-10-24 |
Family
ID=54767384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016028520A BR112016028520A2 (pt) | 2014-06-04 | 2015-06-04 | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10023621B2 (enExample) |
| EP (2) | EP3152237B1 (enExample) |
| JP (3) | JP6568110B2 (enExample) |
| KR (4) | KR102077286B1 (enExample) |
| CN (2) | CN106795224B (enExample) |
| AU (2) | AU2015269333B2 (enExample) |
| BR (1) | BR112016028520A2 (enExample) |
| CA (1) | CA2950754C (enExample) |
| EA (2) | EA202090632A1 (enExample) |
| MA (2) | MA51074A (enExample) |
| MX (2) | MX382908B (enExample) |
| WO (1) | WO2015187977A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3811965A1 (en) | 2005-11-23 | 2021-04-28 | Acceleron Pharma, Inc. | Activin-actriia antagonists in use for promoting bone growth |
| CA2729096C (en) | 2008-06-26 | 2020-04-28 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| MX362105B (es) | 2013-01-25 | 2019-01-04 | Shire Human Genetic Therapies | Folistatina en el tratamiento de distrofia muscular de duchenne. |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| CN106795224B (zh) | 2014-06-04 | 2021-05-18 | 阿塞勒隆制药公司 | 用促滤泡素抑制素多肽治疗病症的方法和组合物 |
| CN107135646B (zh) | 2014-06-13 | 2022-03-15 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| KR20170129233A (ko) | 2015-03-26 | 2017-11-24 | 악셀레론 파마 인코포레이티드 | 폴리스타틴-관련된 융합 단백질 및 이들의 용도 |
| BR112018067747A2 (pt) * | 2016-03-04 | 2019-01-08 | Shire Human Genetic Therapies | proteínas de fusão recombinantes de folistatina-fc e uso no tratamento da distrofia muscular de duchenne |
| US10905766B2 (en) | 2017-03-23 | 2021-02-02 | Oregon State University | Therapeutic compositions and methods for treatment of muscle wasting diseases |
| KR101822633B1 (ko) * | 2017-08-22 | 2018-01-26 | (주)진셀팜 | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 |
| WO2019046903A1 (en) * | 2017-09-08 | 2019-03-14 | Baker Heart and Diabetes Institute | THERAPEUTIC METHOD FOR INCREASING MUSCLE MASS IN A SUBJECT |
| CN108218985B (zh) * | 2017-12-12 | 2021-04-30 | 山西农业大学 | 一种利用特征多肽制备fst蛋白特异性抗体的方法及其应用 |
| WO2019178613A1 (en) * | 2018-03-16 | 2019-09-19 | Immusoft Corporation | B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength |
| CN111902157B (zh) * | 2018-03-21 | 2023-08-04 | 松阳生技股份有限公司 | 促进局部肌肉增长、减缓或防止局部肌肉萎缩的组合物及其用途 |
| WO2019191204A1 (en) * | 2018-03-28 | 2019-10-03 | Acceleron Pharma Inc. | Follistatin polypeptides for the treatment of muscle contracture |
| AU2019269702A1 (en) * | 2018-05-17 | 2020-12-24 | Housey Pharmaceutical Research Laboratories, L.L.C. | Inhibition of follistatin |
| US12246042B2 (en) | 2018-08-29 | 2025-03-11 | Myos Corp. | Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
| IL317374A (en) | 2022-06-15 | 2025-02-01 | UCB Biopharma SRL | Fusion protein for the prevention, treatment or alleviation of kidney disease |
| WO2023242251A1 (en) | 2022-06-15 | 2023-12-21 | UCB Biopharma SRL | Follistatin-fc fusion proteins |
| EP4630443A1 (en) * | 2022-12-07 | 2025-10-15 | Kamino ApS | Extracellular matrix binding compounds for the localized loading of therapeutic or diagnostic agents |
| TW202530250A (zh) * | 2024-01-25 | 2025-08-01 | 大陸商四川至善唯新生物科技有限公司 | 編碼卵泡抑素的核酸及其用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5041538A (en) | 1987-08-28 | 1991-08-20 | The Salk Institute For Biological Studies | Mammalian follistatin |
| US5182375A (en) | 1987-08-28 | 1993-01-26 | The Salk Institute For Biological Studies | DNA encoding follistatin |
| WO1992013947A1 (en) | 1991-02-08 | 1992-08-20 | Progenics Pharmaceuticals, Inc. | CD4-GAMMA2 AND CD4-IgG2 CHIMERAS |
| JPH08501314A (ja) | 1992-09-16 | 1996-02-13 | ジェネンテク，インコーポレイテッド | Ｈｇｆによる肝臓障害に対する保護 |
| CA2174098C (en) | 1993-10-14 | 2011-01-25 | Douglas A. Melton | Method of inducing and maintaining neuronal cells |
| US6686198B1 (en) | 1993-10-14 | 2004-02-03 | President And Fellows Of Harvard College | Method of inducing and maintaining neuronal cells |
| US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
| US5545616A (en) | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
| GB2306481A (en) | 1995-10-21 | 1997-05-07 | Univ Manchester | Pharmaceutical comprising a stimulator of activin and/or inhibin |
| WO1999006559A1 (en) | 1997-08-01 | 1999-02-11 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (gdf) receptors |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| ATE322681T1 (de) | 1999-01-21 | 2006-04-15 | Metamorphix Inc | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
| EP1174149A1 (en) | 1999-04-19 | 2002-01-23 | Kyowa Hakko Kogyo Co., Ltd. | Proliferation inhibitor for androgen-independent tumor |
| WO2001009368A1 (en) | 1999-07-30 | 2001-02-08 | The General Hospital Corporation | Follistatin antagonists |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| AU2003216345A1 (en) | 2002-02-21 | 2003-09-09 | Wyeth | Follistatin domain containing proteins |
| CN1993048A (zh) * | 2002-02-21 | 2007-07-04 | 惠氏公司 | 包含促滤泡素抑制素结构域的蛋白质 |
| AU2003217612A1 (en) | 2002-02-21 | 2003-09-09 | Wyeth | GASP1: a follistatin domain containing protein |
| ATE474593T1 (de) | 2003-03-21 | 2010-08-15 | Celldex Therapeutics Ltd | Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway |
| JP5110877B2 (ja) | 2003-06-02 | 2012-12-26 | ワイス・エルエルシー | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
| US20070135336A1 (en) | 2003-09-15 | 2007-06-14 | De Kretser David | Follistatin isoforms and uses thereof |
| WO2005033134A2 (en) | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Secreted protein therapeutics and uses thereof |
| WO2005032578A1 (en) | 2003-10-06 | 2005-04-14 | Monash University | Therapeutic method |
| JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| ES2426005T3 (es) * | 2004-07-23 | 2013-10-18 | Acceleron Pharma Inc. | Polipéptidos del receptor ACTRII, procedimientos y composiciones |
| US20060034831A1 (en) | 2004-08-12 | 2006-02-16 | Wyeth | Combination therapy for diabetes, obesity and cardiovascular diseases using GDF-8 inhibitors |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| EP3327033A1 (en) | 2005-08-19 | 2018-05-30 | Wyeth LLC | Antagonist antibodies against gdf-8 and uses in treatment of als and other gdf-8-associated disorders |
| AU2006321906C1 (en) | 2005-12-06 | 2014-01-16 | Amgen Inc. | Uses of myostatin antagonists |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| CA2693178C (en) | 2006-11-29 | 2018-12-04 | Nationwide Children's Hospital, Inc. | Myostatin inhibition for enhancing muscle and/or improving muscle function |
| UA116871C2 (uk) | 2006-12-18 | 2018-05-25 | Акселерон Фарма Інк. | СПОСІБ ЛІКУВАННЯ МІЄЛОДИСПЛАСТИЧНОГО СИНДРОМУ, ТАЛАСЕМІЇ ТА СЕРПОПОДІБНО-КЛІТИННОЇ АНЕМІЇ ЗА ДОПОМОГОЮ ЗАСТОСУВАННЯ АНТАГОНІСТА АКТИВІНУ ПОЛІПЕПТИДУ ActRII |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| EP2318028B1 (en) * | 2008-06-26 | 2020-02-19 | Acceleron Pharma Inc. | Antagonists of soluble activin-actriia and uses for increasing red blood cell levels |
| CA2729096C (en) * | 2008-06-26 | 2020-04-28 | Acceleron Pharma Inc. | Methods for dosing an actriib antagonist and monitoring of treated patients |
| MX340451B (es) * | 2009-09-09 | 2016-07-08 | Acceleron Pharma Inc | Antagonistas de actriib y dosificacion y usos de los mismos. |
| CA2805054A1 (en) * | 2010-08-25 | 2012-03-01 | F. Hoffmann-La Roche Ag | Antibodies against il-18r1 and uses thereof |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| AU2013243952A1 (en) * | 2012-04-02 | 2014-10-30 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013170315A1 (en) | 2012-05-17 | 2013-11-21 | Paranta Biosciences Limited | A method of treatment and agents useful for same |
| EP2866826B1 (en) * | 2012-06-27 | 2025-08-06 | Meiragtx UK II Limited | Combination for treating an inflammatory disorder |
| MX362105B (es) * | 2013-01-25 | 2019-01-04 | Shire Human Genetic Therapies | Folistatina en el tratamiento de distrofia muscular de duchenne. |
| WO2014187807A1 (en) * | 2013-05-21 | 2014-11-27 | Arcarios B.V. | Follistatin derivatives |
| CN106795224B (zh) | 2014-06-04 | 2021-05-18 | 阿塞勒隆制药公司 | 用促滤泡素抑制素多肽治疗病症的方法和组合物 |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| KR20170129233A (ko) | 2015-03-26 | 2017-11-24 | 악셀레론 파마 인코포레이티드 | 폴리스타틴-관련된 융합 단백질 및 이들의 용도 |
| US20180362604A1 (en) | 2017-05-12 | 2018-12-20 | Shire Human Genetic Therapies, Inc. | Recombinant Follistatin-FC Fusion Proteins and Use in Treating Duchenne Muscular Dystrophy |
-
2015
- 2015-06-04 CN CN201580041740.2A patent/CN106795224B/zh not_active Expired - Fee Related
- 2015-06-04 KR KR1020177000297A patent/KR102077286B1/ko not_active Expired - Fee Related
- 2015-06-04 CA CA2950754A patent/CA2950754C/en active Active
- 2015-06-04 MX MX2016015868A patent/MX382908B/es unknown
- 2015-06-04 US US14/731,009 patent/US10023621B2/en active Active
- 2015-06-04 KR KR1020207018965A patent/KR102305109B1/ko not_active Expired - Fee Related
- 2015-06-04 MA MA051074A patent/MA51074A/fr unknown
- 2015-06-04 EA EA202090632A patent/EA202090632A1/ru unknown
- 2015-06-04 EA EA201692529A patent/EA035455B1/ru not_active IP Right Cessation
- 2015-06-04 EP EP15802909.0A patent/EP3152237B1/en active Active
- 2015-06-04 WO PCT/US2015/034245 patent/WO2015187977A1/en not_active Ceased
- 2015-06-04 EP EP20160287.7A patent/EP3721892B1/en active Active
- 2015-06-04 JP JP2016570806A patent/JP6568110B2/ja not_active Expired - Fee Related
- 2015-06-04 CN CN202110533308.2A patent/CN113583104A/zh active Pending
- 2015-06-04 BR BR112016028520A patent/BR112016028520A2/pt not_active Application Discontinuation
- 2015-06-04 AU AU2015269333A patent/AU2015269333B2/en not_active Ceased
- 2015-06-04 KR KR1020207003791A patent/KR102132144B1/ko not_active Expired - Fee Related
- 2015-06-04 KR KR1020217029755A patent/KR20210119546A/ko not_active Ceased
- 2015-06-04 MA MA051075A patent/MA51075A/fr unknown
-
2016
- 2016-12-01 MX MX2021006017A patent/MX2021006017A/es unknown
-
2018
- 2018-06-12 US US16/006,025 patent/US10954279B2/en active Active
-
2019
- 2019-08-01 JP JP2019142333A patent/JP6856716B2/ja not_active Expired - Fee Related
-
2020
- 2020-08-03 AU AU2020210315A patent/AU2020210315A1/en not_active Abandoned
-
2021
- 2021-03-18 JP JP2021044545A patent/JP2021095416A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016028520A2 (pt) | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina | |
| GEP20217326B (en) | Constructs having a sirp-alpha domain or variant thereof | |
| PH12019501405A1 (en) | Anti-neuropilin antigen-binding proteins and methods of use thereof | |
| MX393740B (es) | Anticuerpos contra alfa-sinucleina y sus usos. | |
| BR112016020368A2 (pt) | proteínas fc multiméricas | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| EA201991207A1 (ru) | Новые агонисты tnfr и их применение | |
| BR112017001183A2 (pt) | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado | |
| BR122020006914B8 (pt) | Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado | |
| NZ759601A (en) | Aggrecan binding immunoglobulins | |
| BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| MX359201B (es) | Polipeptidos que se unen al complemento humano 5 (c5). | |
| BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
| BR112016019176A2 (pt) | anticorpos il-21 | |
| MX2019009952A (es) | Formulaciones de evolocumab de baja viscosidad y alta concentracion y metodos de elaboracion de las mismas. | |
| AR095334A1 (es) | Composiciones nutricionales que contienen un componente peptídico con propiedades estimulantes de la adiponectina y método para promover un peso corporal saludable | |
| BR112014031841A2 (pt) | formulação farmacêutica | |
| BR112015021483A2 (pt) | arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer | |
| MX2022002635A (es) | Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso. | |
| MX2018004041A (es) | Tratamiento de trastornos de acidos biliares. | |
| MX2019006446A (es) | Métodos para inducir tolerancia inmunológica a factores de coagulación. | |
| TW201613977A (en) | Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use | |
| BR112017023762A2 (pt) | formulações de depósito injetáveis | |
| BR112019006174A2 (pt) | proteina terapêutica | |
| NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |